These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
575 related items for PubMed ID: 16219143
21. [Two patterns of mediastinal lymph node resection for non-small cell lung cancer of stage IIIA: survival analysis of 219 cases]. Zhang GQ, Han F, Gao SL, A DL, Pang ZL. Ai Zheng; 2007 May; 26(5):519-23. PubMed ID: 17672944 [Abstract] [Full Text] [Related]
22. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE. J Clin Oncol; 2008 Apr 10; 26(11):1886-92. PubMed ID: 18398154 [Abstract] [Full Text] [Related]
23. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ, Christenson RH. Clin Cancer Res; 2003 May 10; 9(5):1728-33. PubMed ID: 12738727 [Abstract] [Full Text] [Related]
24. [Clinical study of the effects of radiotherapy in combination with traditional Chinese medicine on non-small cell lung cancer]. Cai HB, Dai FG, Min QF, Shi M, Miao JX, Luo RC. Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec 10; 22(12):1112-3. PubMed ID: 12480588 [Abstract] [Full Text] [Related]
25. Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. McCulloch M, Broffman M, van der Laan M, Hubbard A, Kushi L, Kramer A, Gao J, Colford JM. Integr Cancer Ther; 2011 Sep 10; 10(3):260-79. PubMed ID: 21824893 [Abstract] [Full Text] [Related]
26. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. Eur J Cancer; 2010 Mar 10; 46(4):735-43. PubMed ID: 20045311 [Abstract] [Full Text] [Related]
27. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR. Cancer; 2006 Aug 15; 107(4):781-92. PubMed ID: 16847887 [Abstract] [Full Text] [Related]
28. [Establishment and evaluation of a prognostic prediction model for patients after complete resection of non-small cell lung cancer and multidisciplinary therapy]. Wei WD, Fu JH, Lin P, Li XD, Yang H, Rong TH, Chen LK. Zhonghua Zhong Liu Za Zhi; 2008 Sep 15; 30(9):672-5. PubMed ID: 19173908 [Abstract] [Full Text] [Related]
29. [Prognostic analysis of 151 patients with maxillary sinus malignant neoplasms]. Guo GF, Yang AK, Xie RH, Chen ZH, Wu QL, Ou SM, Liu WW, Xia LP, Chen MY, Zhang JX, Wu JH. Ai Zheng; 2004 Nov 15; 23(11 Suppl):1546-50. PubMed ID: 15566677 [Abstract] [Full Text] [Related]
30. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR, SWOG S9712. J Clin Oncol; 2006 Nov 20; 24(33):5242-6. PubMed ID: 17114656 [Abstract] [Full Text] [Related]
31. [Whole brain irradiation for non-small-cell lung cancer with brain metastasis]. Shi AH, Zhu GY, Yu R, Ma HM, Liu CQ, Su X, Sun Y, Cai Y, Xu XN, Zhang SW, Xu B. Zhonghua Zhong Liu Za Zhi; 2007 Jul 20; 29(7):545-8. PubMed ID: 18069640 [Abstract] [Full Text] [Related]
33. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D. Cancer Chemother Pharmacol; 2007 Jun 20; 60(1):81-9. PubMed ID: 17031646 [Abstract] [Full Text] [Related]
34. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer]. Wang WH, Bao Y, Chen M, Zhang L, Li KX, Xu GC, Deng XW, Lu TX, Cui NJ. Ai Zheng; 2006 Oct 20; 25(10):1279-83. PubMed ID: 17059776 [Abstract] [Full Text] [Related]
35. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A. Lung Cancer; 2007 Nov 20; 58(2):238-45. PubMed ID: 17658655 [Abstract] [Full Text] [Related]
36. [Prognostic effect of mediastinal lymph node dissection in patients with stage I non-small cell lung cancer]. Su XD, Wang X, Rong TH, Long H, Fu JH, Lin P, Zhang LJ, Wang SY, Wen ZS, Ma GW. Zhonghua Wai Ke Za Zhi; 2007 Nov 15; 45(22):1543-5. PubMed ID: 18282391 [Abstract] [Full Text] [Related]
39. [Prospective randomized study of HMVP, MVP, and HVP regimens in treatment of advanced non-small cell lung cancer]. Gao JF, Li CS, Zhang BC, Du GZ, Zhang XH, Wang J, Zhu YZ, Ou WL, Yang B. Ai Zheng; 2004 Apr 15; 23(4):435-8. PubMed ID: 15087034 [Abstract] [Full Text] [Related]